Orthofix Medical Inc. (OFIX)
NASDAQ: OFIX · Real-Time Price · USD
17.95
-0.15 (-0.83%)
Feb 21, 2025, 4:00 PM EST - Market closed
Orthofix Medical Revenue
Orthofix Medical had revenue of $196.61M in the quarter ending September 30, 2024, with 6.85% growth. This brings the company's revenue in the last twelve months to $784.25M, up 17.32% year-over-year. In the year 2023, Orthofix Medical had annual revenue of $746.64M with 62.06% growth.
Revenue (ttm)
$784.25M
Revenue Growth
+17.32%
P/S Ratio
0.86
Revenue / Employee
$479,957
Employees
1,634
Market Cap
685.94M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 746.64M | 285.93M | 62.06% |
Dec 31, 2022 | 460.71M | -3.77M | -0.81% |
Dec 31, 2021 | 464.48M | 57.92M | 14.25% |
Dec 31, 2020 | 406.56M | -53.39M | -11.61% |
Dec 31, 2019 | 459.96M | 6.91M | 1.53% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
OFIX News
- 5 days ago - Orthofix to Participate in the Canaccord Genuity 2025 Musculoskeletal Conference - Business Wire
- 17 days ago - Top 2 Health Care Stocks That May Crash In February - Benzinga
- 25 days ago - Orthofix to Report Fourth Quarter and Full-Year 2024 Financial Results - Business Wire
- 2 months ago - Bronstein, Gewirtz & Grossman, LLC Encourages Orthofix Medical Inc. (OFIX) Investors to Inquire about Securities Investigation - Accesswire
- 3 months ago - Orthofix to Participate in Upcoming Investor Conferences - Business Wire
- 3 months ago - Orthofix Medical Inc. (OFIX) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Orthofix Reports Third Quarter 2024 Results, Reiterates Full-Year 2024 Financial Guidance, and Introduces New Three-Year Financial Targets - Business Wire
- 3 months ago - Orthofix Announces New Term Loan - Business Wire